Eagle's Eye View: Your Weekly CV Update From ACC.org

エピソード

• 
  CV Subspecialty Training; a Novel Left Atrium Staging Framework; the (IL)-6 Inflammatory Biomarker, HF Risk & Diabetes 16.09.2026 10分

  In this week's View, Dr. Eagle looks at a recent article on proposed changes to the current cardiovascular (CV) subspecialty training path. He then examines an article on a novel left atrium (LA) staging framework that stratifies new-onset atrial fibrillation risk in hypertrophic cardiomyopathy (HCM). Finally, Dr. Eagle explores the results of a Look AHEAD ancillary study on the inflammatory biomarker interleukin (IL)-6 that identified residual inflammatory risk of incident heart failure (HF) in patients with type 2 diabetes (T2D) and overweight/obesity.  Subscribe to Eagle's Eye View   
• 
  Top Five Trials from ESC 26: SINGLE-AF, REBOOT-PARADOX, ViVA, REACT, NOTION-4 09.09.2026 10分

  In this week's View, Dr. Eagle looks at some of the important trials presented at this year's European Society of Cardiology (ESC) Congress. First, he evaluates the SINGLE-AF trial on DOAC therapy versus no anticoagulation in atrial fibrillation (AFib) with patients with intermediate stroke risk. Dr. Eagle then examines REBOOT-PARADOX and its study of the potential value of transcatheter aortic valve replacement (TAVR) in symptomatic patients with low-flow, low-gradient aortic stenosis. Next, Dr. Eagle covers ViVA, a randomized trial that looked at vericiguat for the treatment of coronary vasospasm, followed by a summary of the REACT trial that investigated the use of imaging to detect silent atherosclerosis in early adulthood. Finally, Dr. Eagle explores NOTION-4, which looks at short-term direct oral anticoagulant (DOAC) therapy and subclinical leaflet thickening after TAVR.  Subscribe to Eagle's Eye View      
• 
  M-TEER, MR, & LV Dysfunction, Stress Perfusion CMR & CAD; Sacubutril/Valsartan, Cardiac Remodeling, and Non-Obstructive HCM. 02.09.2026 7分

  In this week's View, Dr. Eagle evaluates how sacubitril/valsartan promotes cardiac remodeling, but not functional capacity, in nonobstructive hypertrophic cardiomyopathy. Next, he examines the prognostic value of stress perfusion cardiac magnetic resonance in patients with suspected coronary artery disease. Finally, Dr. Eagle explores a study on mitral transcatheter edge-to-edge repair (M-TEER) and its effectiveness for treatment of patients with ventricular functional mitral regurgitation (MR) and very severe left ventricular (LV) dysfunction.   Subscribe to Eagle's Eye View   
• 
  : M-TEER, MR, & LV Dysfunction, Stress Perfusion CMR & CAD; Sacubutril/Valsartan, Cardiac Remodeling, and Non-Obstructive HCM. 02.09.2026 8分

  In this week's View, Dr. Eagle evaluates how sacubitril/valsartan promotes cardiac remodeling, but not functional capacity, in nonobstructive hypertrophic cardiomyopathy. Next, he examines the prognostic value of stress perfusion cardiac magnetic resonance in patients with suspected coronary artery disease. Finally, Dr. Eagle explores a study on mitral transcatheter edge-to-edge repair (M-TEER) and its effectiveness for treatment of patients with ventricular functional mitral regurgitation (MR) and very severe left ventricular (LV) dysfunction.   Subscribe to Eagle's Eye View   
• 
  CAC, CRF & Dementia; Athletes & Arrhythmia; Vutrisaran & Amyloid Burden; NT0proBNP Screening & Heart Failure 26.08.2026 9分

  In this week's View, Dr. Eagle looks at the relationship between lower cardiorespiratory fitness (CRF) and higher coronary artery calcium scores (CAC) and later-life dementia. He follows this with a look at a new State of the Art Review related to guidance on treating athletes with arrhythmia. He then offers a perspective on the use of vutrisiran in the treatment of amyloid burden. Finally, Dr. Eagle explores the TARTAN-HF study on NT-proBNP screening and its ability to identify undiagnosed heart failure (HF) among patients with diabetes.    Subscribe to Eagle's Eye View   
• 
  Antithrombotic Regimens after Valve-in-Vave TAVR; TAV vs. SAVR Outcomes in Low-Risk Patients; Sex Difference and Delayed Diagnosis on Acoramidis; Lifestyle Intervention and ANOCA 12.08.2026 8分

  In this week's View, Dr. Eagle looks at the wide variation in antithrombotic regimens after valve-in-valve transcatheter aortic valve replacement (TAVR). Next, he examines PARTNER-3, a 7-year study on TAVR versus surgical aortic valve replacement (SAVR) outcomes in low-risk patients. He then offers a perspective on the effect of sex difference and delayed diagnosis in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) from amyloidosis. Finally, Dr. Eagle explores the prospective SAMCRO trial which evaluates lifestyle intervention in addition to medical therapy in patients with invasively confirmed angina with no obstructive coronary artery disease (ANOCA).  Subscribe to Eagle's Eye View     
• 
  Venous Thromboembolism & Cancer; Influenza Vaccines & AFib; the DAPT-MVD Trial & Cutting PCI in CAD; the AC Expect Consensus Decision Pathway on HFpEF 29.07.2026 9分

  In this week's View, Dr. Eagle looks at a post-hoc analysis of the API-CAT trial that showed recurrent venous thromboembolism (VTE) is uncommon but associated with poor short-term survival of patients with cancer-associated thrombosis. He follows with a look at an observational cohort study on how influenza vaccination is associated with lower risks of incident atrial fibrillation (AFib), then reviews evidence from the DAPT-MVD trial demonstrating that extended DAPT lowers the risk of cardiovascular events after percutaneous coronary intervention (PCI) in multivessel coronary artery disease. Finally, Dr. Eagle explores ACC's updated expert consensus decision pathway addressing the management of heart failure preserved ejection fraction (HFpEF).  Subscribe to Eagle's Eye View      
• 
  Age, BMI, & TAVR; Enhanced Radiation Protections in Cath Labs; Particulate Matter and CV Risk; the SUMMIT Trial & Tirzepatide. 22.07.2026 9分

  In this week's View, Dr. Eagle looks at age, body mass index (BMI), and cardiovascular outcomes after transcatheter aortic valve replacement (TAVR). He follows this with an examination of a new consensus statement about enhanced radiation protection in cath labs, then offers a perspective on particulate matter in the environment and increased coronary heart disease risk. Finally, Dr. Eagle provides an analysis of the SUMMIT Trial, showing the benefit of tirzepatide for heart failure with preserved ejection fraction (HFpEF) both in women and men.   Subscribe to Eagle's Eye View   
• 
  Mechanical Leaflet Splitting and TAVR; Ambient Temperature & Marathons; AFib, PVI with PA & IRF; the SHaRE Registry as a Predictor of MACE 15.07.2026 10分

  In this week's View, Dr. Eagle looks at the feasibility of mechanical leaflet splitting in high-risk patients undergoing valve-in-valve TAVR. He follows this with an examination of lower ambient temperature and it association with greater SCA risk at marathon races, then offers a commentary on two studies that provide new insights on the durability of pulmonary vein isolation (PVI) with pulsed field ablation (PA) vs radiofrequency ablation IRF) in patients with persistent atrial fibrillation (AFib). Finally, Dr. Eagle discusses the SHaRe Registry and its use in predicting major adverse cardiovascular events MACE for patients with mild hypertrophic cardiomyopathy (HCM). Subscribe to Eagle's Eye View  
• 
  Guideline-Directed Medical Therapy & Atrial Fibrillation; Anti-Platelet Therapy & ASCVD; DOACs & Prevention of Thrombotic Events; Sugar-Sweetened Beverages and Fruit Juice & Hypertension 08.07.2026 9分

  In this week's View, Dr. Eagle looks at withdrawing guideline-directed medical therapy (GDMT) for patients with atrial fibrillation (AF). He follows this with commentary on two important recently released ACC scientific statements: one on anti-platelet therapy for atherosclerotic cardiovascular disease (ASCVD), and the other examining the use of direct oral anticoagulants (DOACs) for primary and secondary prevention of thrombotic events. Finally, Dr. Eagle summarizes a recent longitudinal study on sugar-sweetened beverages and fruit juice and their potential relationship to the development of hypertension later in a young person's life.   Subscribe to Eagle's Eye View   
• 
  Genotype and Hypertrophic Cardiomyopathy; PARTNER 2A & TAVR 10 Years Later; Clopidogrel vs. Aspirin after PCI; LDL & Risk Assessment of ASCVD 01.07.2026 8分

  In this week's View, Dr. Eagle looks at how genotype independently predicts heart failure outcomes in patients with hypertrophic cardiomyopathy (HCM). He then examines the ten-year follow-up of the PARTNER 2A trial and compares the transcatheter aortic valve replacement (TAVR) outcomes to results from the Partner 2 SAPIEN XT and SAPIEN 3 studies. He follows this with a report on how clopidogrel may offer a long-term edge over aspirin after percutaneous coronary intervention (PCI). Finally, Dr. Eagle summarizes HELIUS cohort findings demonstrating that LDL-C, Lp(a), and hsCRP provide complementary, independent insights for identifying long-term atherosclerotic cardiovascular disease (ASCVD) risk across diverse ethnic populations.   Subscribe to Eagle's Eye View   
• 
  Lifestyle Intervention, Metformin and Multimorbidity Risk in Prediabetes; Hypertension, Hyperlipidemia and Chronic Kidney Disease, Resistance Training & Myocardial Infarction 24.06.2026 9分

  In this week's View, Dr. Eagle reviews 21-year follow-up data from the Diabetes Prevention Program (DPP), showing that lifestyle intervention—but not metformin—reduces multimorbidity risk in prediabetes. He also highlights low rates of hypertension and hyperlipidemia treatment among U.S. adults with cardiovascular-kidney-metabolic (CKM) syndrome, and summarizes evidence that resistance training, particularly when combined with aerobic exercise, is associated with a lower risk of cardiovascular (CV) disease, especially myocardial infarction, in women. Finally, he discusses the CAMERA-MRI II study in patients with atrial fibrillation and left ventricular systolic dysfunction (LVSD), where catheter ablation significantly improved left ventricular ejection fraction (LVEF) regardless of late gadolinium enhancement status.  Subscribe to Eagle's Eye View 
• 
  Race and Sex Disparities in Mitral Valve Edge-to-Edge Repair 17.06.2026 8分

  In this week's View, Dr. Eagle highlights a study showing race and sex disparities in M-TEER outcomes, with Black patients presenting with more advanced disease, lower success, and higher heart failure readmissions than White patients, and women having lower success rates than men. He reviews the SOGALDI-PEF trial, where patients with low plasma renin levels experienced greater blood pressure reduction with spironolactone/dapagliflozin compared to dapagliflozin alone. Next, he discusses the FAVOR III trial, which found that QFR-guided percutaneous coronary intervention improved five-year outcomes versus angiography guidance, with most benefits occurring in the first two years. Lastly, Dr. Eagle examines two renal disease studies addressing optimal chronic kidney disease (CKD) GFR thresholds and the benefits of finerenone in CKD patients. 
• 
  Impact of Semaglutide And Survival Outcomes In Patients With T2D and CKD 10.06.2026 7分

  In this week's View, Dr. Eagle highlights several noteworthy developments shaping cardiovascular and renal care. He first examines the FLOW analysis, underscoring the benefits of semaglutide for patients with chronic kidney disease, with particular attention to its impact on both renal and cardiovascular outcomes. He then reviews a phase I study exploring an innovative therapeutic approach involving a single intravenous infusion—Verve-2—which targets PCSK9 expression in the liver and may represent a promising future strategy for treating familial hyperlipidemia. Finally, Dr. Eagle discusses recent findings on antihypertensive drug combinations, emphasizing those regimens that provide optimal efficacy while minimizing adverse effects that often lead to early treatment discontinuation. 
• 
  Postpartum Cardiovascular Care; 'Low Risk' Chest Pain in the ER; Heart Failure Risk Detection & CV Outcomes with Implantable Devices 03.06.2026 9分

  In this week's View, Dr. Eagle looks at recent research found in ACC's new expert decision pathway for postpartum cardiovascular care. He then offers insights from the ACC Chest Pain - MI Registry examining 'low risk' chest pain and its evaluation in the emergency departments. Next, a discussion of how negative patient outcomes were associated with late pericardial effusion post-left atrial appendage occlusion (LAAO) device implantation. Finally, Dr. Eagle summarizes the ALLEVIATE-HF trial that explored heart failure (HF) risk detection with an insertable cardiac monitor paired with a centrally coordinated nurse-led diuretic intervention.  Subscribe to Eagle's Eye View   
• 
  Maintaining Weight Loss with Tirzepatide; the new Dyslipidemia Guidelines; Sacubitril/Valsartan & HFpEF & Functional MR; Digitoxin & Heart Failure 27.05.2026 9分

  In this week's View, Dr. Eagle examines recent research into maintaining weight loss with tirzepatide. He then offers insights into the new dyslipidemia guidelines, including addressing reproductive and hormone risk factors in cardiovascular risk assessment. Next, Dr. Eagle looks at the use of sacubitril/valsartan to improve exercise tolerance in patients with heart failure with reduced ejection fraction (HFpEF) and functional mitral regurgitation (MR). Finally, Dr. Eagle summarizes a new study on the use of digitoxin and digoxin in patients with heart failure.  Subscribe to Eagle's Eye View   
• 
  HCM, NT-proBNP and HCM Risk Evaluation; Arrhythmic Burden in Cardiac Amyloidosis Obesity and Heart Failure; Postural Orthostatic Tachycardia Syndrome (POTS) 20.05.2026 8分

  In this week's View, Dr. Eagle reviews evidence supporting the use of cardiac magnetic resonance (CMR) and NT-proBNP in hypertrophic cardiomyopathy (HCM) risk assessment. He then examines the EXCALIBUR study, which aims to better characterize arrhythmic burden in patients with cardiac amyloidosis. Next, he discusses research identifying obesity as a significant risk factor for heart failure, highlighting key findings and clinical implications. Finally, he summarizes new evidence on the use of ivabradine and propranolol in treating postural orthostatic tachycardia syndrome (POTS).    Subscribe to Eagle's Eye View   
• 
  Rhythm Control & Tricuspid Valve Regurgitation; Benefits of Blood Pressure Control on Cardiovascular Disease; Switching DOAC Therapy in AFIB Patients with Stroke; Pulsed Field Ablation & Persistent AFib 13.05.2026 9分

  In this week's View, Dr. Eagle examines the role of rhythm control in improving moderate-to-severe and severe secondary tricuspid valve regurgitation. He then explores evidence showing that blood pressure reduction can deliver comparable cardiovascular benefits for patients with chronic kidney disease (CKD). Another study reviewed in this episode assesses the outcomes of continuing versus switching direct oral anticoagulant (DOAC) therapy in patients with atrial fibrillation (AFib) who experience breakthrough stroke. Finally, Dr. Eagle summarizes the AVANTE-GUARD trial, which evaluates pulsed field ablation as a first-line treatment for patients with persistent AFib.   Subscribe to Eagle's Eye View
• 
  Pulsed Field Ablation and PAS; TRIDENT & Antihypertensive Polypharmacy; NOBLE and PCI vs. CABG 06.05.2026 8分

  In this week's View, Dr. Eagle looks at the NOBLE trial evaluating whether percutaneous coronary intervention (PCI) or coronary artery bypass grafting (CABG) is best for patients with unprotected left main coronary artery disease (CAD). He then explores a report highlighting nanosecond pulsed field ablation (nsPFA) and its safety and efficacy at one year for paroxysmal atrial fibrillation. Finally, Dr. Eagle presents a summary of the TRIDENT trial, which compares a triple‑pill antihypertensive strategy with conventional therapy and finds a positive impact on hypertension management and stroke risk following intracerebral hemorrhage.  Subscribe to Eagle's Eye View       
• 
  Benefits of Endovascular Therapy for Post-Thrombotic Syndrome; Sex Hormones & CV Risk; Asundexian & Stroke Risk; Cardiorespiratory Fitness & Longer Lifespans 29.04.2026 9分

  In this week's View, Dr. Eagle looks at endovascular therapy for post-thrombotic syndrome and how it reduces severity and improves quality of life. He then explores current evidence and strategies to address sex hormone-associated thrombotic and cardiovascular risk. Next, Dr. Eagle examines the OCEANIC-STROKE trial which studied asundexian and its potential to lower recurrent stroke risk in patients with noncardioembolic stroke or transient ischemic attack. Finally, Dr. Eagle asks the question, is high cardiorespiratory fitness associated with longer lifespan and lower multimorbidity?  Subscribe to Eagle's Eye View